ReShape Lifesciences Announces 2017 Weight Loss Contest Winner

ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the winners of its 2017 weight loss contest, which recognizes patients for their successful weight loss with the ReShape Balloon™.

The contest winner lost a total of 80 pounds, or 41% total weight loss (TWL), with 60 pounds, or 28% TWL, lost during the 6-month ReShape Balloon implant period, followed by continued weight loss of the remaining 20 pounds after device removal. The patient, a female, age 53, had the ReShape Balloon placed by Dr. Vivek Kumbhari, MD, Director of Endoscopy at Johns Hopkins Bayview Medical Center & Director of Bariatric Endoscopy at Johns Hopkins Weight Management Center.

The second and third place winners, a 39-year-old male and a 33-year-old female, had 6-month TWL of 25% and 21%, respectively.

“In my experience, the ReShape Balloon has been a safe and effective option for patients who have failed diet and exercise and who are either not indicated for or are afraid of surgical solutions,” commented Dr. Kumbhari. “We have found that the ReShape program, which includes the six-month dual balloon implant coupled with diet, exercise and monthly behavior modification coaching, has helped patients lose significant weight, while often also improving related comorbidities such as high blood pressure and high cholesterol.”

The ReShape Balloon is the only FDA-approved dual balloon that is designed to help people lose weight by taking up room in the stomach, thereby helping people feel full and eat less. The balloon is inserted in a single visit and is designed to stay in the stomach for up to six months.

About ReShape Lifesciences Inc.
ReShape Lifesciences is a medical device company focused on technology to treat obesity and metabolic diseases. The FDA-approved ReShape® Integrated Dual Balloon System involves a non-surgical weight loss procedure that uses advanced interconnected balloon technology designed to take up room in the stomach to help people with a 30-40 BMI, and at least one co-morbidity, lose weight. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc System, is designed to help patients with a Body Mass Index (BMI) of 40-45, or 35-39.9 with a minimum of one related comorbid condition, feel full, eat less and lose weight by intermittently blocking hunger signals on the vagus nerve. The Gastric Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.